Clinical Trials
18 trialsNCT06903858 2026-05-22
PICC-3
Sun Yat-sen University
Phase 2 Recruiting
NCT03926338 2025-11-20
PICC
Sun Yat-sen University
Phase 2 Recruiting
NCT07154316 2025-09-04
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
Fudan University
Phase 2 Recruiting
NCT05578287 2023-12-07
DETECT
Sun Yat-sen University
Phase 2 Unknown
NCT00503035 2023-02-13
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT02280694 2020-02-12
LDMchemoCRC
HaEmek Medical Center, Israel
Phase 2 Completed
NCT02615574 2017-09-26
A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cancer
University of Pittsburgh
Phase 2 Withdrawn
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT00081224 2016-12-15
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT00230399 2015-04-21
Combination Chemotherapy Treatments in Patients With Metastatic Colorectal Cancer
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT00043043 2013-06-19
Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00258232 2013-04-08
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00336960 2013-03-05
Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00466505 2012-12-19
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00072553 2009-02-09
Celecoxib, Leucovorin, Fluorouracil, and Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00037180 2008-09-29
For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy
Pfizer
Phase 2 Terminated